載入...
Immunotherapy for Glioblastoma: Current Progress and Challenges
Glioblastoma is a highly lethal brain cancer with a median survival rate of less than 15 months when treated with the current standard of care, which consists of surgery, radiotherapy and chemotherapy. With the recent success of immunotherapy in other aggressive cancers such as advanced melanoma and...
Na minha lista:
| 發表在: | Front Immunol |
|---|---|
| Main Authors: | , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Frontiers Media S.A.
2021
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8158294/ https://ncbi.nlm.nih.gov/pubmed/34054867 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2021.676301 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|